Status
Conditions
Treatments
About
Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Each participant must meet all of the following inclusion criteria to participate in this study:
Exclusion criteria
All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study:
11 participants in 1 patient group
Loading...
Central trial contact
Jay Detsky, MD; Amit Singnurkar, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal